Sevelamer reduces endothelial inflammatory response to advanced glycation end products

BACKGROUND: Advanced glycation end products (AGEs) have been related to the pathogenesis of cardiovascular diseases (CVD), chronic kidney disease (CKD) and diabetes mellitus. We sought to investigate the binding capacity of sevelamer to both AGEs and uremic serum in vitro and then test this pharmace...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Kidney J
Huvudupphovsmän: Gregório, Paulo C, Favretto, Giane, Sassaki, Guilherme L, Cunha, Regiane S, Becker-Finco, Alessandra, Pecoits-Filho, Roberto, Souza, Wesley M, Barreto, Fellype C, Stinghen, Andréa E M
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
CKD Complications
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5798142/
https://ncbi.nlm.nih.gov/pubmed/29423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfx074
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk